Long-term safety and efficacy of emicizumab for up to 5.8 years and patients' perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A.

Midori ShimaAzusa NagaoMasashi TakiTadashi MatsushitaKoichi OshidaKagehiro AmanoSayaka NagamiNorihiro OkadaShingo MaisawaKeiji Nogami

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2020)

Long-term emicizumab prophylaxis for up to 5.8 years was safe and efficacious, and may improve patients' daily lives and feelings, regardless of inhibitor status.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
prognostic factors
healthcare
physical activity
randomized controlled trial
clinical trial
early onset
study protocol